Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer

Table 1 Laboratory parameters of the 3 tumor markers in pancreatic cancer group, pancreatitis group and normal group (mean ± SD, × 10³U/L)

Group	No. of cases	TSGF	CA242	CA19-9
Critical value		>71	>20	>37
Pancreatic cancer	96	80.7 ± 7.6b	90.2 ± 10.9b	643.5 ± 203.6b
Pancreatitis	52	61.4 ± 6.7	21.1 ± 10.5	30.9 ± 5.9
Normal
22-59 yr	113	54.3 ± 5.1	17.5 ± 8.3	14.5 ± 5.0
60-68 yr	87	56.6 ± 5.8	19.2 ± 9.6	17.2 ± 5.9

^bP < 0.01 vs normal group.

Table 2 Evaluation of the value of diagnosis in pancreatic cancer by a single tumor marker of 96 cases

Value of diagnosis	Sensitivity (%)	Specificity (%)	Positive Likelihood ratio	Negative Likelihood ratio
TSGF	91.6 (88) a	83.0	5.4	0.10
CA242	82.3 (79)	93.5b	12.6	0.19
CA19-9	85.4 (82)	86.5	6.3	0.17

(), No. of cases;

^aP < 0.05,

^bP < 0.01 vs the other two indexes. sensitivity = truepositive/patients × 100% = TP/(TP + FN) × 100%, specificity = true negative/normal × 100% = TN/(TN + FP) × 100% positive likelihood ratio = true positive/false positive = sensitivity/(1-specificity) negative likelihood ratio = (1-true positive)/(1-false positive) = (1-sensitivity)/specificity.

Table 3 Analyses of The different combinations of the 3 markers to the diagnosis in pancreatic cancer (No. of cases)

Group	No. of cases	1 Item (+)	2 Item (+)	3 Item (+)
Pancreatic cancer	96	90 (93.8)	86 (89.5)	74 (77.0)
Normal	200	42 (21.0)	9 (4.5)	0 (100)
Positive likelihood rate (%)		68.2	90.5	100

(), sensitivity (%).

Table 4 The content of the 3 markers in the different positions of pancreatic cancer (mean ± SD, × 10³U/L)

Position of pancreatic cancer	No. of cases	TSGF	CA242	CA19-9
Head	64	88.5 ± 9.0b	106.4 ± 12.6b	653.7 ± 217.8
Body	18	78.2 ± 6.7	82.5 ± 10.4	633.9 ± 192.4
Tail	10	77.1 ± 5.7	81.6 ± 8.2	659.4 ± 211.0
Whole	4	74.5 ± 3.1	83.0 ± 9.5	615.3 ± 187.1

^bP < 0.001 vs body, tail and whole of pancreatic cancer.

Table 5 Analyses of the sensitivity of the 3 tumor markers in different stages of pancreatic cancer (No. of cases)

Clinical stages	No. of cases	TSGF	CA242	CA19-9
I	10	6 (60.0) bd	3 (30.0) d	4 (40.0) d
II	12	9 (75.0)	6 (50.0)	7 (58.3)
III	25	22 (88.0)	20 (80.0)	21 (84.0)
IV	49	46 (93.8)	40 (81.6)	42 (85.7)

Note: (), sensitivity (%) ;

^dP < 0.01 vs the sensitivity of stage II, III, IV;

^bP < 0.01 vs the sensitivity of CA242, CA19-9.